Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
EAI141 was a prospective, multi-center trial designed to assess 3'-deoxy-3'-<sup>18</sup>F-fluorothymidine (FLT) PET/CT as a treatment response biomarker. The primary objective was to evaluate the negative predictive value (NPV) of post-treatment 'day 14' FLT-uptake (clinically non-responding patients with high FLT uptake). Among 87 patients enrolled from 9 centers, 61 were evaluable for the primary endpoint. The NPV for FLT PET/CT was 0.20 (3/15, 95% CI 0.04-0.48) compared to the NPV for nadir bone marrow of 0.25 (4/16, 95% CI 0.07-0.52). This first multi-center molecular imaging study in patients with AML demonstrated the feasibility of FLT PET/CT imaging. While molecular imaging did not predict response status more accurately than the nadir marrow, this study showed limitations in the accuracy of the 'day 14' marrow as a predictor of response and suggested added benefit by combining a marrow assessment and molecular imaging at an earlier time point.
Authors
- Scott B. Perlman (ORCID: https://orcid.org/0000-0001-9744-7105)
- Ryan J. Mattison (ORCID: https://orcid.org/0000-0001-8574-8365)
- Justin Romanoff (ORCID: https://orcid.org/0000-0001-7058-9621)
- Lale Kostakoglu (ORCID: https://orcid.org/0000-0001-5478-8161)
- Gregory A. Wiseman
- Robert Jeraj (ORCID: https://orcid.org/0000-0002-2192-2931)
- Stephen A. Strickland (ORCID: https://orcid.org/0000-0002-6861-2041)
- Fenghai Duan (ORCID: https://orcid.org/0000-0002-5084-0070)
- Jennifer Holter‐Chakrabarty (ORCID: https://orcid.org/0000-0003-1425-7002)
- Barry A. Siegel (ORCID: https://orcid.org/0000-0001-6246-5792)
- Charles D. Arnold (ORCID: https://orcid.org/0000-0001-6510-3172)
- Daniel A. Arber (ORCID: https://orcid.org/0000-0002-2160-9689)
- David A. Mankoff (ORCID: https://orcid.org/0000-0002-6971-5413)
- Jennifer G. Whisenant (ORCID: https://orcid.org/0000-0002-3435-2464)
- Elisabeth Paietta (ORCID: https://orcid.org/0000-0002-0561-5544)
- Kebede H. Begna (ORCID: https://orcid.org/0000-0003-2730-8593)
- Aric C. Hall (ORCID: https://orcid.org/0000-0002-6520-6056)
- Geoffrey L. Uy (ORCID: https://orcid.org/0000-0002-7809-0996)
- Mark R. Litzow
Institutions
- Montefiore Medical Center (US)
- University of Wisconsin–Madison (US)
- Breast Cancer Research Foundation (US)
- Vanderbilt University (US)
- Washington University in St. Louis (US)
- WinnMed (US)
- California University of Pennsylvania (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- NYU Langone Health (US)
- Hinge Health (US)
- ECOG-ACRIN Cancer Research Group (US)
- Mayo Clinic in Arizona (US)
- Oklahoma State University Oklahoma City (US)
- Washington University Medical Center (US)
- Vanderbilt-Ingram Cancer Center
- University of Pennsylvania (US)
- University of Oklahoma (US)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1080/10428194.2025.2567516
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00